Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China

Overview of attention for article published in Frontiers in Public Health, December 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 13 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 20 publications that cite this research output.

20

The most recent citing publications are shown below. View all 20 publications that cite this research output on Dimensions.

Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens

Article in Risk Management and Healthcare Policy (April 2024)

A multicenter, real‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative

Article in Cancer Medicine (February 2024)

Clinical outcomes and medical resource utilization of toripalimab combination therapy versus bevacizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer

Article in Current Medical Research and Opinion (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.